In this Comment, we outline the Nordic AI-Health Initiative platform, built on unique large-scale longitudinal and multimodal health data sets from across the region. The platform is designed to enable secure, regulation-compliant access and to deliver generalizable models for responsible AI-driven discovery in medicine
This is a preview of subscription content, access
Access options
Access through your institution
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Subjects
References
Han, R. et al. Lancet Digit. Health6, e367–e373 (2024)
Moor, M. et al. Nature616, 259–265 (2023)
Njolstad, P. R. et al. Nat. Genet.51, 924–930 (2019)
Laugesen, K. et al. Clin. Epidemiol.13, 533–554 (2021)
Kurki, M. I. et al. Nature613, 508–518 (2023)
Milani, L. et al. Nat. Commun.16, 3270 (2025)
Arnar, D. O. et al. Eur. J. Intern. Med.41, 3–9 (2017)
Shmatko, A. et al. Nature647, 248–256 (2025)
Acosta, J. N. et al. Nat. Med.28, 1773–1784 (2022)
Bronstein, M. M. et al. Preprint at https://doi.org/10.48550/arXiv.2104.13478 (2021)
Rieke, N. et al. npj Digit. Med.3, 119 (2020)
Lekadir, K. et al. BMJ388, e081554 (2025)
Obermeyer, Z. et al. Science366, 447–453 (2019)
Reas, E. T. et al. Alzheimers Dement.19, 5151–5158 (2023)
Kallioniemi, O. et al. Sitra Rep. www.sitra.fi/julkaisut/terveystiedon-tulevaisuus-tekoalyn-aikakaudella/ (2026)
Acknowledgements
The authors thank S. Sævarsdóttir for constructive discussions. Generative AI tools were used to improve readability, grammar, and language, and all authors reviewed and approved the final version of the manuscript. O.A.A. received funding from Nordforsk, Novo Nordisk Foundation, Research Council of Norway, KG Jebsen Stiftelsen, European Union’s Horizon 2020 and Horizon Europe research and innovation programs. H.H. received funding from the Lundbeck Foundation. T.L. received funding from Knut and Alice Wallenberg Foundation, European Research Council, Swedish Research Council, and National Institutes of Health. P.R.N. was supported by funds from the European Research Council, Novo Nordisk Foundation, Danish Diabetes & Endocrinology Academy, Trond Mohn Foundation, KG Jebsen Stiftelsen, Meltzer Foundation. M.V. was supported by the Research Council of Norway, European Research Council, University of Bergen. S.R., J.V. and L.M.: this work has received funding from the European Union’s Horizon Europe research and innovation program under grant agreement no. 101060011. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. T.W. received funding from the European Partnership for Personalised Medicine, Novo Nordisk Foundation, US National Institute of Mental Health. S.B. received funding from Novo Nordisk Foundation. O.K. received funding from the Research Council of Finland, Finnish Medical Foundation, Sigrid Juselius Foundation and the Jane and Aatos Erkko Foundation, KAW, Vetenskapsrådet, and CancerFonden (Sweden).
Author information
Authors and Affiliations
Center for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
Ole A. Andreassen, Hakon Heimer & Olav B. Smeland
Institute of Clinical Medicine, University of Oslo, Oslo, Norway
Ole A. Andreassen, Anders M. Dale & Olav B. Smeland
Institute of Biological Psychiatry, Mental Health Services, Amager and Hvidovre Hospital, Copenhagen University Hospital, Roskilde, Denmark
Hakon Heimer & Thomas Werge
Centre for Healthy Brain Aging, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
Dag Aarsland
Centre for Age-Related Diseases, Stavanger University Hospital, Stavanger, Norway
Dag Aarsland
J. Craig Venter Institute, San Diego, CA, USA
Anders M. Dale
Amgen deCODE genetics, Reykjavik, Iceland
Daníel Gudbjartsson & Hreinn Stefánsson
Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden
Bo Jacobsson
Department of Obstetrics and Gynecology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
Bo Jacobsson
Department of Genetics and Bioinformatics, Division of Health Data and Digitalisation, Institute of Public Health, Oslo, Norway
Bo Jacobsson
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Ingrid Kockum
Department of Gene Technology, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
Tuuli Lappalainen
New York Genome Center, New York, NY, USA
Tuuli Lappalainen
Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
Andres Metspalu & Lili Milani
Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway
Pål R. Njølstad & Marc Vaudel
Department of Pediatric and Adolescent Medicine, Haukeland University Hospital, Bergen, Norway
Pål R. Njølstad
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health, University of Copenhagen, Copenhagen, Denmark
Pål R. Njølstad
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
Aarno Palotie, Samuli Ripatti & Olli Kallioniemi
Medical Affairs and Health Impact, AbbVie Scandina
Anders Sandvik
University of Iceland, Reykjavik, Iceland
Kári Stefánsson
Computational Biology Unit, Department of Informatics, University of Bergen, Bergen, Norway
Marc Vaudel
Institute of Computer Science, University of Tartu, Tartu, Estonia
Jaak Vilo
STACC, Tartu, Estonia
Jaak Vilo
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Thomas Werge
Department of Public Health, Section for Health Data Science and AI, Copenhagen University, Copenhagen, Denmark
Søren Brunak
Department of Oncology–Pathology, Karolinska Institutet, Stockholm, Sweden
Olli Kallioniemi
Authors
- Ole A. AndreassenView author publications
Search author on:PubMed Google Scholar
- Hakon HeimerView author publications
Search author on:PubMed Google Scholar
- Dag AarslandView author publications
Search author on:PubMed Google Scholar
- Anders M. DaleView author publications
Search author on:PubMed Google Scholar
- Daníel GudbjartssonView author publications
Search author on:PubMed Google Scholar
- Bo JacobssonView author publications
Search author on:PubMed Google Scholar
- Ingrid KockumView author publications
Search author on:PubMed Google Scholar
- Tuuli LappalainenView author publications
Search author on:PubMed Google Scholar
- Andres MetspaluView author publications
Search author on:PubMed Google Scholar
- Lili MilaniView author publications
Search author on:PubMed Google Scholar
- Aarno PalotieView author publications
Search author on:PubMed Google Scholar
- Samuli RipattiView author publications
Search author on:PubMed Google Scholar
- Anders SandvikView author publications
Search author on:PubMed Google Scholar
- Olav B. SmelandView author publications
Search author on:PubMed Google Scholar
- Hreinn StefánssonView author publications
Search author on:PubMed Google Scholar
- Kári StefánssonView author publications
Search author on:PubMed Google Scholar
- Marc VaudelView author publications
Search author on:PubMed Google Scholar
- Jaak ViloView author publications
Search author on:PubMed Google Scholar
- Thomas WergeView author publications
Search author on:PubMed Google Scholar
- Søren BrunakView author publications
Search author on:PubMed Google Scholar
- Olli KallioniemiView author publications
Search author on:PubMed Google Scholar
Ethics declarations
Competing interests
O.A.A. is a consultant to Precision-Health.ai and Ledidi, and has received speaker’s honoraria from Eli Lilly and Company, Bristol Myers Squibb, H. Lundbeck A/S, Otsuka Pharmaceutical Co, Sunovion Pharmaceuticals Inc., and Janssen Pharmaceuticals. D.A. has received research support and/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals, Evonik, Roche Diagnostics, and GE Health, Sanofi, and served as a paid consultant for H. Lundbeck, Eisai, Heptares, Eli Lilly, Enterin, Acadia, EIP Pharma, Biogen, and Takeda, Eli Lilly, Eisai, BioArctic. T.L. is an advisor with equity in Variant Bio. A.S. is an employee at AbbVie, a biopharmaceutical company. AbbVie has not provided funding for the development of this paper and has no role in the decision to publish. L.M. has received travel reimbursement from Pacific Biosciences for attending meetings to present research results. A.M.D. is a founding director of, and holds equity in, CorTechs Labs Inc. (DBA Cortechs.ai), Precision Pro Inc., and Precision Health and Wellness Inc. A.M.D. is the president and a board of trustees member of the J. Craig Venter Institute. H.S. and D.G. are employees at Amgen deCODE genetics. S.B. has received speakers’ honoraria from Sanofi and Roche. O.K. is founder and shareholder in Sartar Therapeutics and received honoraria from KAW, Novo Nordisk Foundation and Sitra.
Rights and permissions
About this article
Cite this article
Andreassen, O.A., Heimer, H., Aarsland, D. et al. An AI-Health infrastructure for the Nordic region: technical foundations, data assets, and a roadmap for deployment.
Nat Med (2026). https://doi.org/10.1038/s41591-026-04575-4
Published:14 August 2026
Version of record:14 August 2026
DOI
:https://doi.org/10.1038/s41591-026-04575-4
